What does this score mean?
More than 600 postmortem human frontal cortex samples, transcriptomics, mass spectrometry, and computational validation were used together. The role of an MKKS-derived microprotein in microglial mitochondrial respiration was also functionally tested. Disease causality and therapeutic effect are nevertheless not proven.
What did the study investigate?
It investigated whether microproteins produced by small open reading frames that are not included in standard protein databases are actually expressed in the human brain and whether they are associated with Alzheimer’s disease.
How was it done?
Researchers evaluated more than 600 postmortem frontal cortex samples from individuals with and without Alzheimer’s disease. Transcriptomic data, mass spectrometry, and spectra predicted by deep learning were combined.
What was found?
1,067 high-confidence microproteins not found in Reviewed UniProtKB records were identified. A portion of these were differentially expressed in Alzheimer’s disease. In particular, a 63-amino acid microprotein produced from the MKKS gene locus was decreased in Alzheimer’s; its loss was shown to impair microglial mitochondrial respiration.
Limitations of the study
Postmortem tissues may reflect end-stage biology rather than the cause of the disease. Expression differences associated with Alzheimer’s do not imply causality. The biological function for the majority of microproteins is not yet known.
What does this mean clinically?
This study demonstrates that the human proteome is broader than classical protein databases and that there may be overlooked novel biomarkers or drug targets in neurodegeneration. However, as of today, no microprotein is a clinical diagnostic or therapeutic standard.
What do we not know yet?
It is not known which microproteins are the cause of the disease and which are the consequence, whether they can be translated into measurable biomarkers in peripheral blood, and whether they can be therapeutically targeted.
Reference
Miller B, Vieira de Souza E, Lau C, et al. A microprotein atlas of the human frontal cortex in Alzheimer’s disease. Nature Aging. 2026;6:1979–1997. DOI: 10.1038/s43587-026-01207-x. Publication date: September 14, 2026.
Related reading: Healthy Aging and Biological Age · Mitochondrial Health and Aging
Written and medically reviewed by: Dr. Kerem Çağlayan · All Scientific Research
Detailed evaluation
Why is it so important?
Classical proteomic analyses typically search for well-annotated proteins. A significant portion of proteins shorter than 100–150 amino acids produced from small ORFs has been excluded by these filters. The new atlas experimentally makes a large portion of this “dark proteome” visible.
MKKS microprotein
One of the strongest mechanistic examples of the study is the 63-amino acid microprotein produced from the MKKS locus. Its decrease in Alzheimer’s tissue and the fact that its experimental loss impairs microglial energy production are noteworthy in terms of the neuroimmune–mitochondrial axis.
Conclusion
Microproteins open a new layer of research in Alzheimer’s biology. Although it is early for clinical application, it is a high-priority area in terms of biomarker and target discovery.
Medical evaluation note: This content has been prepared for the purpose of interpreting scientific data; it is not a personal diagnostic or treatment recommendation.
